Cencora (Cencora) Risk Assessment

View and export this data going back to 1995. Start your Free Trial

What is Cencora Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cencora is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Cencora's Risk Assessment

For the Medical Distribution subindustry, Cencora's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cencora's Risk Assessment Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cencora's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cencora's Risk Assessment falls into.

Cencora (NYSE:COR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cencora Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cencora's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cencora (Cencora) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cencora Inc (NYSE:COR) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

ABG:Germany C1CO34:Brazil ABC:Austria

Address

1 West First Avenue, Conshohocken, PA, USA, 19428-1800

Website

https://www.cencora.com

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the U.S. pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Executives

Leslie E Donato	officer: EVP & Chief Strategy Officer	227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Elizabeth S Campbell	officer: Executive Vice President	1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Steven H Collis	officer: President & CEO	1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Lazarus Krikorian	officer: Senior Vice President	1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Silvana Battaglia	officer: Executive Vice President	227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Walgreens Boots Alliance, Inc.	10 percent owner	108 WILMOT ROAD, DEERFIELD IL 60015
Gina Clark	officer: Executive Vice President	1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Werner Baumann	director	1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Lauren M Tyler	director	C/O ALLEGHANY CORPORATION, 1411 BROADWAY, 34TH FLOOR, NEW YORK NY 10018
Robert P. Mauch	officer: Executive Vice President	1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Redonda Miller	director	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Lorence H. Kim	director	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Walgreens Boots Alliance Holdings Llc	10 percent owner	108 WILMOT ROAD, DEERFIELD IL 60015
Lon R Greenberg	director	460 NORTH GULPH ROAD, KING OF PRUSSIA PA 19406
John G. Chou	officer: Executive Vice President	1300 MORRIS DRIVE, CHESTERBROOK PA 19087